Defining effective antitumor T cell responses to guide next-generation adoptive cell therapies for solid tumors

Wednesday 09:00 PST / 12:00 EST / 17:00 GMT / 18:00 CET

Sponsor

Defining effective antitumor T cell responses to guide next-generation adoptive cell therapies for solid tumors

Drawing on longitudinal patient data, Cristina Puig-Saus (Assistant Professor, UCLA) will explore the landscape of neoepitope-specific T cells and how their clonal evolution correlates with clinical response or resistance to immune checkpoint blockade.

She will then connect these biological insights to practical strategies for fine-tuning CAR-T design.

This webinar will:

Provide a framework for understanding the evolution of neoantigen-specific T-cell responses in patients with melanoma, with or without response to immune checkpoint blockade
Explain how persistence and recurrence of TCR clonotypes impact resistance to checkpoint inhibitors
Describe advanced methods for isolating neoantigen-specific T cells and fine-tuning CAR-T cell design
Provide a blueprint for the design of CAR-T cell therapies and the path to clinical translation
Describe real-life experience of moving a novel CAR-T therapy from preclinical modeling into a Phase I clinical trial protocol

Register today to gain data-driven insights into T cell biology and engineering strategies that help inform the design of new adoptive cell therapies for solid tumors.

Cristina Puig-Saus, PhD

Assistant Professor, Department of Microbiology, Immunology, and Molecular Genetics; Department of Surgery, Division of Surgical Oncology at UCLA

Dr. Cristina Puig Saus' research efforts are mainly focused on the understanding of natural T cell responses to cancer and the design and clinical translation of new cellular therapies for solid tumors. Her lab is currently studying the neoepitope-specific T cell responses induced after immune checkpoint blockade in patients that respond or do not respond to therapy, with the objective to define what constitutes an effective antitumor T cell response. They are also interested in developing novel CAR-T cell therapies for melanoma. They are currently starting the IND-enabling studies for one of their candidates and in parallel designing additional CAR-T cell based strategies and combination therapies. Her additional interests include the design of strategies to improve T cell gene editing for their use in adoptive T cell therapy for cancer.

In 28 Days

You have registered for this webinar